Vaccination against autoimmune diseases moves closer to the clinic

Eden, Willem van

doi:10.1080/21645515.2019.1593085

Cited by 10 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increases in the number and inhibitory activity of Treg cells changed the immune response to Th2 subsets vivo is better than in vitro expansion, and thus they have attempted to combine the two approaches, such as the application of autoantigen in an incomplete adjuvant (137), and the combination of tolDCs and Treg-induced peptide, which inactivate effector cells and promote the function of Treg cells (138).…”

Section: Factors Induce the Inhibition Of Soluble Protein Secretion Bmentioning

confidence: 99%

Function and Role of Regulatory T Cells in Rheumatoid Arthritis

et al. 2021

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a systemic and heterogeneous autoimmune disease with symmetrical polyarthritis as its critical clinical manifestation. The basic cause of autoimmune diseases is the loss of tolerance to self or harmless antigens. The loss or functional deficiency of key immune cells, regulatory T (Treg) cells, has been confirmed in human autoimmune diseases. The pathogenesis of RA is complex, and the dysfunction of Tregs is one of the proposed mechanisms underlying the breakdown of self-tolerance leading to the progression of RA. Treg cells are a vital component of peripheral immune tolerance, and the transcription factor Foxp3 plays a major immunosuppressive role. Clinical treatment for RA mainly utilizes drugs to alleviate the progression of disease and relieve disease activity, and the ideal treatment strategy should be to re-induce self-tolerance before obvious tissue injury. Treg cells are one of the ideal options. This review will introduce the classification, mechanism of action, and characteristics of Treg cells in RA, which provides insights into clinical RA treatment.

show abstract

Section: Factors Induce the Inhibition Of Soluble Protein Secretion Bmentioning

confidence: 99%

Function and Role of Regulatory T Cells in Rheumatoid Arthritis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Numerous studies have demonstrated that the administration of soluble antigens or immunodominant peptides under non-inflammatory conditions can indeed induce a state of unresponsiveness. Clonal deletion, induction of anergy, or modification in the cytokine profile of pro-inflammatory effector cells and, notably, induction and expansion of regulatory T cells (Tregs) were discussed as possible mechanisms in induced tolerance ( 3 – 8 ). Tregs play a pivotal role in maintaining self-tolerance and in modulating immune responses in inflammatory diseases.…”

Section: Introductionmentioning

confidence: 99%

Tolerogenic Immunomodulation by PEGylated Antigenic Peptides

et al. 2020

View full text Add to dashboard Cite

Current treatments for autoimmune disorders rely on non-specific immunomodulatory and global immunosuppressive drugs, which show a variable degree of efficiency and are often accompanied by side effects. In contrast, strategies aiming at inducing antigen-specific tolerance promise an exclusive specificity of the immunomodulation. However, although successful in experimental models, peptide-based tolerogenic “inverse” vaccines have largely failed to show efficacy in clinical trials. Recent studies showed that repetitive T cell epitopes, coupling of peptides to autologous cells, or peptides coupled to nanoparticles can improve the tolerogenic efficacy of peptides, suggesting that size and biophysical properties of antigen constructs affect the induction of tolerance. As these materials bear hurdles with respect to preparation or regulatory aspects, we wondered whether conjugation of peptides to the well-established and clinically proven synthetic material polyethylene glycol (PEG) might also work. We here coupled the T cell epitope OVA 323–339 to polyethylene glycols of different size and structure and tested the impact of these nano-sized constructs on regulatory (Treg) and effector T cells in the DO11.10 adoptive transfer mouse model. Systemic vaccination with PEGylated peptides resulted in highly increased frequencies of Foxp3 + Tregs and reduced frequencies of antigen-specific T cells producing pro-inflammatory TNF compared to vaccination with the native peptide. PEGylation was found to extend the bioavailability of the model peptide. Both tolerogenicity and bioavailability were dependent on PEG size and structure. In conclusion, PEGylation of antigenic peptides is an effective and feasible strategy to improve Treg-inducing, peptide-based vaccines with potential use for the treatment of autoimmune diseases, allergies, and transplant rejection.

show abstract

“…146 Moreover, the combination of tolergenic dendritic cell (tolDC) and Treg-inducing peptides to inactivate effector cells, promotes Treg cell function. 147…”

Section: Limitations Of Treg Therapymentioning

confidence: 99%

Cell‐based therapies for the treatment of rheumatoid arthritis

Moghaddam,

Mousavi,

Ghotloo

2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

Autoimmune diseases, including rheumatoid arthritis that is the most prevalent rheumatic autoimmune disorder, affect autologous connective tissues caused by the breakdown of the self‐tolerance mechanisms of the immune system. During the last two decades, cell‐based therapy, including stem cells and none‐stem cells has been increasingly considered as a therapeutic option in various diseases. This is partly due to the unique properties of stem cells that divide and differentiate from the specialized cells in the damaged tissue. Moreover, stem cells and none‐stem cells, impose immunomodulatory properties affecting the diseases caused by immunological abnormalities such as rheumatic autoimmune disorders. In the present review, the efficacy of cell‐based therapy with four main types of stem cells, including mesenchymal stem cells, hematopoietic stem cells, embryonic stem cells, and human amniotic membrane cells, as well as none‐stem cells, including regulatory T cells, chimeric antigen receptor T cells, and tolerogenic dendritic cells will be evaluated. Moreover, other related issues, including safety, changes in immunological parameters, suitable choice of stem cell and none‐stem cell origin, conditioning regimen, limitations, and complications will be discussed.

show abstract

Vaccination against autoimmune diseases moves closer to the clinic

Cited by 10 publications

References 33 publications

Function and Role of Regulatory T Cells in Rheumatoid Arthritis

Function and Role of Regulatory T Cells in Rheumatoid Arthritis

Tolerogenic Immunomodulation by PEGylated Antigenic Peptides

Cell‐based therapies for the treatment of rheumatoid arthritis

Contact Info

Product

Resources

About